Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo

P. Abedinpour,V. Baron,J. Welsh,P. Borgström
DOI: https://doi.org/10.1002/pros.21297
2011-06-01
The Prostate
Abstract:Hormonal ablation is the standard of treatment for advanced androgen‐dependent prostate cancer. Although tumor regression is usually achieved at first, the cancer inevitably evolves toward androgen‐independence, in part because of the development of mechanisms of resistance and in part because at the tissue level androgen withdrawal is not fully attained. Current research efforts are focused on new therapeutic strategies that will increase the effectiveness of androgen withdrawal and delay recurrence. We used a syngeneic pseudo‐orthotropic mouse model of prostate cancer to test the efficacy of combining androgen withdrawal with FDA‐approved COX‐2 inhibitor celecoxib.
What problem does this paper attempt to address?